BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010;16:1186-94. [PMID: 20879017 DOI: 10.1002/lt.22129] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford) 2011;13:783-91. [PMID: 21999591 DOI: 10.1111/j.1477-2574.2011.00355.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
2 Luhnen M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. Appl Health Econ Health Policy. 2016;14:527-543. [PMID: 27329481 DOI: 10.1007/s40258-016-0253-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
3 Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant 2015;29:52-9. [PMID: 25366656 DOI: 10.1111/ctr.12480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Liu M, Huang GL, Xu M, Pan FS, Lu MD, Zheng KG, Kuang M, Xie XY. Percutaneous thermal ablation for the treatment of colorectal liver metastases and hepatocellular carcinoma: a comparison of local therapeutic efficacy. Int J Hyperthermia 2017;33:446-53. [PMID: 28044471 DOI: 10.1080/02656736.2017.1278622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
5 Choudhury RA, Yoeli D, Hoeltzel G, Moore HB, Prins K, Kovler M, Goldstein SD, Holland-cunz SG, Adams M, Roach J, Nydam TL, Vuille-dit-bille RN. STEP improves long-term survival for pediatric short bowel syndrome patients: A Markov decision analysis. Journal of Pediatric Surgery 2020;55:1802-8. [DOI: 10.1016/j.jpedsurg.2020.03.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl. 2011;17:556-566. [PMID: 21506244 DOI: 10.1002/lt.22273] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
8 Spolverato G, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP, Pawlik TM. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg. 2015;39:1474-1484. [PMID: 25665675 DOI: 10.1007/s00268-015-2987-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
9 Tholey DM, Hornung B, Enestvedt CK, Chen Y, Naugler WS, Farsad K, Nabavizadeh N, Schlansky B, Ahn J, Jou JH. Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk? BMJ Open Gastroenterol 2017;4:e000157. [PMID: 28944072 DOI: 10.1136/bmjgast-2017-000157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Kung CM, Mo LR, Yan YH. Consumption of national health insurance medical resources by hepatocellular carcinoma patients treated using radiofrequency ablation therapy. Asia Pac J Clin Oncol 2012;8:275-81. [PMID: 22897713 DOI: 10.1111/j.1743-7563.2012.01516.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat. 2013;20:847-857. [PMID: 24304454 DOI: 10.1111/jvh.12111] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
13 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
14 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013;21:625-33. [PMID: 24238778 DOI: 10.1016/j.tim.2013.09.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
15 Dageforde LA, Feurer ID, Pinson CW, Moore DE. Is liver transplantation using organs donated after cardiac death cost-effective or does it decrease waitlist death by increasing recipient death? HPB (Oxford) 2013;15:182-9. [PMID: 23374358 DOI: 10.1111/j.1477-2574.2012.00524.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
16 Dageforde LA, Landman MP, Feurer ID, Poulose B, Pinson CW, Moore DE. A Cost-Effectiveness Analysis of Early vs Late Reconstruction of Iatrogenic Bile Duct Injuries. Journal of the American College of Surgeons 2012;214:919-27. [DOI: 10.1016/j.jamcollsurg.2012.01.054] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
17 Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastro 2017;15:296-304. [DOI: 10.1007/s11938-017-0133-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
18 Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, Layese R, Costentin C, Cagnot C, Durand-Zaleski I, Chevreul K; ANRS CO12 CirVir and CHANGH groups. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology 2017;65:1237-48. [PMID: 28176349 DOI: 10.1002/hep.28961] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 13.8] [Reference Citation Analysis]
19 Jiao XL, Li SC, Hao L, Wang TG, Chen JF. Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res 2021;:1-7. [PMID: 34433363 DOI: 10.1080/14737167.2021.1973432] [Reference Citation Analysis]
20 Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014;60:37-45. [PMID: 24677184 DOI: 10.1002/hep.27151] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 11.6] [Reference Citation Analysis]
21 Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag Healthc Policy 2012;5:49-54. [PMID: 22826645 DOI: 10.2147/RMHP.S18677] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
22 Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012;56:1651-60. [PMID: 22610658 DOI: 10.1002/hep.25842] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
23 Choudhury RA, Yoeli D, Moore HB, Yaffe H, Hoeltzel GD, Dumon KR, Williams NN, Abt PL, Conzen KD, Nydam TL. Reverse epidemiology and the obesity paradox for patients with chronic kidney disease: a Markov decision model. Surgery for Obesity and Related Diseases 2020;16:948-54. [DOI: 10.1016/j.soard.2020.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Tapper EB, Catana AM, Sethi N, Mansuri D, Sethi S, Vong A, Afdhal NH. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer 2016;122:852-8. [PMID: 26716758 DOI: 10.1002/cncr.29855] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
25 Liu J, Qian LX. Therapeutic efficacy comparison of radiofrequency ablation in hepatocellular carcinoma and metastatic liver cancer. Exp Ther Med 2014;7:897-900. [PMID: 24669247 DOI: 10.3892/etm.2014.1505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
26 Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective. Clinicoecon Outcomes Res. 2012;4:227-235. [PMID: 22977309 DOI: 10.2147/ceor.s31784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Zhao R, Zhou J, Wei Y, Liu F, Chen K, Li Q, Li B. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2017;16:493-8. [DOI: 10.1016/s1499-3872(17)60009-2] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Choudhury RA, Murayama KM, Abt PL, Glick HA, Naji A, Williams NN, Dumon KR. Roux-en-Y gastric bypass compared with aggressive diet and exercise therapy for morbidly obese patients awaiting renal transplant: a decision analysis. Surg Obes Relat Dis 2014;10:79-87. [PMID: 24139923 DOI: 10.1016/j.soard.2013.04.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
29 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
30 Iloabuchi C, Stover A, Rai P, Zhang Y, Kamal KM. Letter to the Editor, Re: Cadier et al. (2017). Hepatology 2017;66:299-300. [PMID: 28370283 DOI: 10.1002/hep.29190] [Reference Citation Analysis]
31 Choudhury R, Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, Talmor DS, Nydam TL, Yaffe MB. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis. World J Emerg Surg. 2020;15:29. [PMID: 32312290 DOI: 10.1186/s13017-020-00305-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
32 Choudhury RA, Hoeltzel G, Prins K, Chow E, Moore HB, Lawson PJ, Yoeli D, Pratap A, Abt PL, Dumon KR, Conzen KD, Nydam TL. Sleeve Gastrectomy Compared with Gastric Bypass for Morbidly Obese Patients with End Stage Renal Disease: a Decision Analysis.J Gastrointest Surg. 2020;24:756-763. [PMID: 31044345 DOI: 10.1007/s11605-019-04225-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
33 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 2016;22:178-87. [PMID: 26479422 DOI: 10.1002/lt.24360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
34 Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS Jr, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl 2014;20:536-43. [PMID: 24493271 DOI: 10.1002/lt.23846] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
35 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
36 Choudhury RA, Murayama KM, Neylan CJ, Savulionyte G, Glick HA, Williams NN, Dempsey DT, Dumon KR. Re-examining the BMI threshold for bariatric surgery in the USA. J Gastrointest Surg 2014;18:2074-9. [PMID: 25297444 DOI: 10.1007/s11605-014-2653-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
37 Ahmed O, Patel M, Ward T, Sze DY, Telischak K, Kothary N, Hofmann LV. Cost Accounting as a Tool for Increasing Cost Transparency in Selective Hepatic Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology 2015;26:1820-1826.e1. [DOI: 10.1016/j.jvir.2015.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
38 Choudhury RA, Foster M, Hoeltzel G, Moore HB, Yaffe H, Yoeli D, Prins K, Ghincea C, Vigneshwar N, Dumon KR, Rame JE, Conzen KD, Pomposelli JJ, Pomfret EA, Nydam TL. Bariatric Surgery for Congestive Heart Failure Patients Improves Access to Transplantation and Long-term Survival. J Gastrointest Surg 2021;25:926-31. [PMID: 32323251 DOI: 10.1007/s11605-020-04587-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54:1259-1271. [PMID: 22412061 DOI: 10.1093/cid/cis011] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 7.5] [Reference Citation Analysis]
40 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 982] [Article Influence: 156.8] [Reference Citation Analysis]
41 Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2. [DOI: 10.1038/nrdp.2016.18] [78495111110.1038/nrdp.2016.18','', '1948-5182')">Reference Citation Analysis]
42 Choudhury RA, Prins K, Dor Y, Moore HB, Yaffe H, Nydam TL. Uncontrolled donation after circulatory death improves access to kidney transplantation: A decision analysis. Clin Transplant 2020;34:e13868. [PMID: 32259310 DOI: 10.1111/ctr.13868] [Reference Citation Analysis]